Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

Source: World Health Organisation
Publication Date: June 30, 2013

View Guideline

2013 World Health Organisation recommendations for providing for persons living with HIV across the continuum of care. Topics include: HIV prevention based on antiretroviral (ARV) drugs; HIV testing and counselling; good practices for linkage to care; and general care for people living with HIV; preparing people living with HIV for antiretroviral therapy (ART); what to expect in the first months of ART; when to start ART; what ART regimen to start with (first-line ART) (for adults, pregnant and breast-feeding women, and ARV drugs for their infants, for children younger than 3 years of age; children 3 years of age and older); tuberculosis cotreatment in children; monitoring response to ART and the diagnosis of treatment failure; monitoring and substitutions for ARV drug toxicities; what ART regimen to switch to (second-line ART) (for adults and adolescents and for children [including adolescents]); third-line ART. Prevention, screening, and management of common coinfections, including tuberculosis; cryptococcal infection; hepatitis B and C; malaria; sexually transmitted infections, and other opportunistic infections. Vaccines for people living with HIV. Preventing and managing other comorbidities and chronic care for people living with HIV.

Guidance on operations and service delivery; adherence to ART; retention across the continuum of care; good practices in providing chronic care; integrating and linking services; decentralising HIV treatment and care; building human resource capacity; task shifting for HIV treatment and care.

Laboratory and diagnostic services; implementation considerations and good practices; increasing access to HIV viral load testing; expanding diagnostic services to point-of-care settings; implementing comprehensive quality management systems; guidance for programme managers.

Monitoring implications of new recommendations; monitoring the outputs and outcomes of scaling up access to ARV drugs; HIV drug resistance; sentinel surveillance for ARV toxicity monitoring; evaluation, including impact and programme performance.

Browse All Guidelines

Keywords: HIV - Resource-Limited Settings, HIV - First-line Therapy, HIV - Drug-Drug Interactions, HIV - Pregnancy, HIV - Viral Hepatitis Coinfection, HIV - Tuberculosis, HIV - Switch Strategies, HIV - Treatment-Experienced Patients, HIV - Prevention, HIV - Sexually Transmitted Diseases, HIV - Monitoring, HIV - Adverse Events, HIV - Drug Resistance